Pancarditis as the Clinical Presentation of Eosinophilic Granulomatosis with Polyangiitis: A Multimodality Approach to Diagnosis

Eosinophilic pancarditis (EP) is a rare, often unrecognized condition caused by endomyocardial infiltration of eosinophil granulocytes (referred as eosinophilic myocarditis, EM) associated with pericardial involvement. EM has a variable clinical presentation, ranging from asymptomatic cases to acute cardiogenic shock requiring mechanical circulatory support (MCS) or chronic restrictive cardiomyopathy at high risk of progression to dilated cardiomyopathy (DCM). EP is associated with high in-hospital mortality, particularly when associated to endomyocardial thrombosis, coronary arteries vasculitis or severe left ventricular systolic dysfunction. To date, there is a lack of consensus about the optimal diagnostic algorithm and clinical management of patients with biopsy-proven EP. The differential diagnosis includes hypersensitivity myocarditis, eosinophil granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome, parasitic infections, pregnancy-related hypereosinophilia, malignancies, drug overdose (particularly clozapine) and Omenn syndrome (OMIM 603554). To our knowledge, we report the first case of pancarditis associated to eosinophilic granulomatosis with polyangiitis (EGPA) with negative anti-neutrophil cytoplasmic antibodies (ANCA). Treatment with steroids and azathioprine was promptly started. Six months later, the patient developed a relapse: treatment with subcutaneous mepolizumab was added on the top of standard therapy, with prompt disease activity remission. This case highlights the role of a multimodality approach for the diagnosis of cardiac involvement associated to systemic immune disorders.

[1]  C. Basso,et al.  Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection. , 2021, Annual review of medicine.

[2]  A. Ihata,et al.  Rituximab and Mepolizumab Combination Therapy for Glucocorticoid-Resistant Myocarditis Related to Eosinophilic Granulomatosis With Polyangiitis. , 2021, Modern rheumatology case reports.

[3]  R. Kerbl [Myocarditis after COVID-19 mRNA vaccination]. , 2021, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde.

[4]  R. Hendel,et al.  Fulminant Eosinophilic Myocarditis and VT Storm , 2021, JACC. Case reports.

[5]  M. De Gaspari,et al.  A case of hypereosinophilic syndrome with Loeffler endocarditis successfully bridged to heart transplantation by biventricular mechanical support. , 2021, Artificial organs.

[6]  Yoshiya Tanaka,et al.  Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis , 2020, Arthritis Research & Therapy.

[7]  Uzair Ashraf,et al.  HYPERSENSITIVITY MYOCARDITIS ASSOCIATED WITH PIPERACILLIN-TAZOBACTAM USE , 2020 .

[8]  H. Fujita,et al.  A Rare Case of Löffler “Pancarditis” Associated with Hypereosinophilic Syndrome , 2020, Internal medicine.

[9]  R. Lodha,et al.  Hypersensitivity Myocarditis Due to Antitubercular Drugs in Children , 2020, The Pediatric infectious disease journal.

[10]  Y. Doi,et al.  Eosinophilic myocarditis associated with hypereosinophilic syndromes , 2020, Geriatrics & gerontology international.

[11]  M. Francone,et al.  Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[12]  W. Koldingsnes,et al.  Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. , 2019, Rheumatology.

[13]  J. Gotlib,et al.  World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management , 2019, American journal of hematology.

[14]  L. Potena,et al.  Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. , 2019, Journal of the American College of Cardiology.

[15]  E. A. Kogan,et al.  Morphologically proved ANCA positive Loeffler's pancarditis: medical and surgical treatment. , 2019, Terapevticheskii arkhiv.

[16]  Uzair Yaqoob,et al.  The Clinicopathological Profile of Eosinophilic Myocarditis , 2018, Cureus.

[17]  K. Klingel,et al.  Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. , 2017, Journal of the American College of Cardiology.

[18]  U. Eriksson,et al.  Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease , 2017, European heart journal.

[19]  S. Yancey,et al.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[20]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[21]  P. Steele,et al.  Kounis syndrome and hypersensitivity myocarditis - One and the same? Insights from cardiac magnetic resonance imaging. , 2015, Journal of cardiology cases.

[22]  S. Iliceto,et al.  Cardiac magnetic resonance features of biopsy-proven endomyocardial diseases. , 2014, JACC. Cardiovascular imaging.

[23]  ThierryFozing,et al.  Management of a Patient With Eosinophilic Myocarditis and Normal Peripheral Eosinophil Count , 2014 .

[24]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[25]  R. Trébossen,et al.  Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. , 2013, Rheumatology.

[26]  B. Carter 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology , 2013 .

[27]  A. Angelini,et al.  2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. , 2012, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[28]  B. Bain Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 , 2010, Haematologica.

[29]  R. Amini,et al.  Eosinophilic myocarditis mimicking acute coronary syndrome secondary to idiopathic hypereosinophilic syndrome: a case report , 2010, Journal of medical case reports.

[30]  A. Ignaszewski,et al.  Eosinophilic myocarditis: case series and review of literature. , 2006, The Canadian journal of cardiology.

[31]  J. Parrillo,et al.  Eosinophilic myocarditis. , 2005, Heart failure clinics.

[32]  Y. Hirota,et al.  Evolution to dilated cardiomyopathy from acute eosinophilic pancarditis in Churg-Strauss syndrome , 2005, Heart and Vessels.

[33]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[34]  A. Gibofsky American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.

[35]  G. Vercellotti,et al.  Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. , 1993, The Journal of clinical investigation.

[36]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[37]  J. Lie,et al.  MYOCARDITIS RELATED TO DRUG HYPERSENSITIVITY , 1985, The Lancet.

[38]  F. Mullick,et al.  Drug related myocarditis. I. Hypersensitivity myocarditis. , 1981, Human pathology.